These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 25386075

  • 1. Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
    Hung MH, Tai WT, Shiau CW, Chen KF.
    World J Gastroenterol; 2014 Nov 07; 20(41):15269-74. PubMed ID: 25386075
    [Abstract] [Full Text] [Related]

  • 2. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
    Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY, Huang JW, Chen KF.
    Hepatology; 2014 Jan 07; 59(1):190-201. PubMed ID: 23908138
    [Abstract] [Full Text] [Related]

  • 3. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF.
    J Hepatol; 2011 Nov 07; 55(5):1041-8. PubMed ID: 21354226
    [Abstract] [Full Text] [Related]

  • 4. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY, Tai WT, Hsieh CY, Hsu WM, Lai YJ, Chen LJ, Shiau CW, Chen KF.
    Cancer Lett; 2014 Jul 28; 349(2):136-43. PubMed ID: 24735751
    [Abstract] [Full Text] [Related]

  • 5. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF.
    Cancer Lett; 2016 Feb 28; 371(2):205-13. PubMed ID: 26679051
    [Abstract] [Full Text] [Related]

  • 6. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF.
    Mol Cancer Ther; 2012 Feb 28; 11(2):452-63. PubMed ID: 22180308
    [Abstract] [Full Text] [Related]

  • 7. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
    Sakurai T, Yada N, Hagiwara S, Arizumi T, Minaga K, Kamata K, Takenaka M, Minami Y, Watanabe T, Nishida N, Kudo M.
    Cancer Sci; 2017 Oct 28; 108(10):1996-2003. PubMed ID: 28777492
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J.
    World J Gastroenterol; 2011 Sep 14; 17(34):3922-32. PubMed ID: 22025881
    [Abstract] [Full Text] [Related]

  • 9. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY, Chao TT, Tai WT, Chang FY, Su WP, Chen YL, Chen PT, Weng CY, Yuan A, Shiau CW, Yu CJ, Chen KF.
    J Thorac Oncol; 2014 Apr 14; 9(4):488-96. PubMed ID: 24736071
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
    Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF.
    Cell Death Dis; 2013 Feb 07; 4(2):e485. PubMed ID: 23392173
    [Abstract] [Full Text] [Related]

  • 12. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT, Chu PY, Shiau CW, Chen YL, Li YS, Hung MH, Chen LJ, Chen PL, Su JC, Lin PY, Yu HC, Chen KF.
    Clin Cancer Res; 2014 Nov 15; 20(22):5768-76. PubMed ID: 25248379
    [Abstract] [Full Text] [Related]

  • 13. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
    Tai WT, Shiau CW, Li YS, Chen YL, Chu PY, Huang JW, Hsu CY, Hsu YC, Chen PJ, Chen KF.
    Mol Cancer Ther; 2014 Jan 15; 13(1):27-36. PubMed ID: 24275147
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
    Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW, Chen KF.
    Breast Cancer Res; 2013 Jan 15; 15(4):R63. PubMed ID: 23938089
    [Abstract] [Full Text] [Related]

  • 16. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, Li YS, Huang JW, Ko CH, Lin MW, Chu PY, Liu CY, Chen KF, Shiau CW.
    Carcinogenesis; 2014 Dec 15; 35(12):2807-14. PubMed ID: 25322871
    [Abstract] [Full Text] [Related]

  • 17. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT, Liu CY, Chen KF, Shiau CW.
    Neoplasia; 2014 Jul 15; 16(7):595-605. PubMed ID: 25047655
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
    Weintraub JL, Salem R.
    J Vasc Interv Radiol; 2013 Aug 15; 24(8):1123-34. PubMed ID: 23562168
    [Abstract] [Full Text] [Related]

  • 20. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
    Li R, Yanjiao G, Wubin H, Yue W, Jianhua H, Huachuan Z, Rongjian S, Zhidong L.
    Oncotarget; 2017 Mar 21; 8(12):19354-19364. PubMed ID: 28423613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.